drugset / Trial / NCT03033316

A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma

NCT03033316

NaSingle-groupOpen-labelTreatment

Summary

Oncocort Dexamethasone sodium phosphate encapsulated in so-called 'long-circulating' PEGylated liposomes is in development with the prospect of providing enhanced and prolonged lesion uptake of dexamethasone and therefore increased therapeutic benefit over existing formulations of dexamethasone in Multiple Myeloma. The current trial is a first-in-man study with Oncocort monotherapy with the objective to assess safety, tolerability, efficacy and dose response after short-term treatment with repeated infusions.

Timeline

Start
2017-01
Primary completion
2020-08
Completion
2020-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule Intravenous

Indications